aTyr Pharma Inc

ATYR is forming an early Stage 1 consolidation near multi-year lows with valuations at the lower bound, and mean reversion is permitted. The 9/21 EMAs have flattened and now support price on shallow pullbacks, with no exhaustion signals visible. Price is holding in the lower half of the base, offering a favorable entry around the EMA cluster within the consolidation band. Under a speculative strategy, buying these pullbacks now aligns with upside breakout potential.

• ↑efzofitimod for pulmonary sarcoidosis addresses key ILD market
• ↑60% workforce reduction yields $13M annual savings, runway to late 2028
• ↓Q2 EPS -$0.11 and negative earnings yield underscore profitability woes